Candel Therapeutics (CADL) Interest Coverage Ratio Growth (1y) (2021 - 2025)
Candel Therapeutics (CADL) Interest Coverage Ratio Growth (1y) (2021 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - | -60.44% |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -347.04% |
| 4 | BeOne Medicines | 472.75 Bn | 467.96 Bn | 1.35 Bn | 787.12% |
| 5 | Vertex Pharmaceuticals | 122.14 Bn | 114.89 Bn | 2.59 Bn | 53.59% |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | -32.04% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 1,378.45% |
| 10 | Candel Therapeutics | 533.82 Mn | 533.82 Mn | - | 68.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 68.14% |
| Sep 30, 2025 | -168.62% |
| Jun 30, 2025 | -101.15% |
| Mar 31, 2025 | 95.20% |
| Dec 31, 2024 | -361.78% |
| Sep 30, 2024 | 96.74% |
| Jun 30, 2024 | 48.54% |
| Mar 31, 2024 | 22.67% |
| Dec 31, 2023 | 88.09% |
| Sep 30, 2023 | 22.60% |
| Jun 30, 2023 | 95.24% |
| Mar 31, 2023 | -5,033.99% |
| Dec 31, 2022 | -37,122.17% |
| Dec 31, 2021 | 22.66% |